Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

NCT05061771 is registered in ClinicalTrials.gov with AKARI Therapeutics as lead sponsor.

NCT NCT05061771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05061771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
Lead sponsor
AKARI Therapeutics
Phase
Phase 3
Overall status
Withdrawn
Start date
May 6, 2022
Completion date
August 1, 2022
Enrollment
0 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid